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Tomoaki Higo, MD, Yasunori Ueda, MD, PHD, Jota Oyabu, MD, Katsuki Okada, MD,
Mayu Nishio, MD, PHD, Akio Hirata, MD, PHD, Kazunori Kashiwase, MD, PHD,
Nobuyuki Ogasawara, MD, Shinichi Hirotani, MD, PHD, Kazuhisa Kodama, MD, PHD
Osaka, Japan
O B J E C T I V E S We sought to examine by angioscopy the neointima formation and thrombogenic
potential of the neointima after deployment of a drug-eluting stent (DES).
B A C KG ROUND Late stent thrombosis after DES implantation, a major safety concern, has been
associated with poor strut coverage by neointima. Intracoronary angioscopy provides a method for
visual evaluation of stent coverage by neointima and detection of thrombus in the stented coronary
segment.
METHOD S Patients undergoing implantation of a sirolimus DES (n  57) were serially examined by
angioscopy immediately after (baseline) and again at 10 months (follow-up) after implantation. The
angioscopic color grade of the neointima from white to yellow was assessed in a semiquantitative
manner. Stent coverage was classiﬁed into not covered (Grade 0), covered by a thin layer (Grade 1), or
buried under neointima (Grade 2). The thrombogenic potential of the neointima was evaluated by the
prevalence of thrombus on the neointima.
R E S U L T S The maximum yellow color grade of the neointima within DES-implanted lesions
increased signiﬁcantly from baseline to follow-up (1.4  1.1 vs. 1.9  0.6, p  0.0008). Even among
lesions without yellow color at baseline, yellow color was detected in 94% (17 of 18) of lesions at
follow-up. The prevalence of thrombus was signiﬁcantly higher on the yellow than on the white
neointimal areas. Thrombus was detected on yellow and/or Grade-0/1 neointima, but never on the white
Grade-2 neointima.
CONC L U S I O N S Sirolimus DES promoted formation of atherosclerotic yellow neointima in the
stent-implanted lesion at 10-month follow-up. Thrombus was detected more often on the yellow area
than on the white area and was never detected where a stent was buried under white neointima. These
data suggest that the increased potential risk of late stent thrombosis in DES lesions may be due to the
newly formed yellow neotima and cholesterol-laden plaque. (J Am Coll Cardiol Img 2009;2:616–24)
© 2009 by the American College of Cardiology Foundation
From the Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.Manuscript received August 14, 2008; revised manuscript received November 26, 2008, accepted December 5, 2008.
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617rug-eluting stents (DES), a treatment of
choice for patients with coronary heart
disease undergoing percutaneous coronary
intervention (PCI), dramatically reduce re-
tenosis. DES have been associated with life-
hreatening late stent thrombosis more than bare-
etal stents (BMS) (1). Pathological examinations
2) of patients dying of late DES thrombosis have
evealed that delayed arterial healing, characterized
y incomplete re-endothelization and persistent
brin deposition, is an important underlying sub-
trate for DES thrombosis. However, the process
See page 625
nd characterization of neointima formation over
ES and its role in the antithrombogenic function
as not been fully clarified. Atherosclerotic change
ithin the neointima after BMS implantation is a
are phenomenon and usually occurs beyond 5
ears. This observation has not been reported in
ES. The yellow color of coronary plaque seen by
ngioscopic examination is associated with lipid-
ich atherosclerotic plaque and has a high throm-
ogenic potential (3,4). Therefore, to characterize
he neointima in DES, we examined the neointima
olor, degree of strut coverage, and prevalence of
hrombus by angioscopy after sirolimus DES im-
lantation at baseline and late follow-up evaluation.
ETHODS
tudy patients. A series of patients who underwent
CI with Cypher (Cordis Corp., Johnson & Johnson
o.,Warren, New Jersey) sirolimus DES were serially
xamined by angioscopy immediately (baseline) and at
0  3 months (follow-up) after stent implantation.
tent thrombosis as a clinical event was not detected
n any patient. Patients who underwent reintervention
f the stented lesion before follow-up examination
ere excluded. Follow-up catheterization was pro-
pectively planned for all patients who received PCI.
Patients (n  12) who underwent implantation
f BMS and follow-up angioscopic examination
ere included retrospectively as a reference.
Intravenous heparin (100 U/kg) was adminis-
ered at the beginning of catheterization, and an
dditional dose was repeated at the time of PCI as
routine protocol in our hospital. Stent implanta-
ion was guided by intravascular ultrasound imaging
o achieve appropriate implantation. Antiplatelet
herapy was oral ticlopidine (200 mg/day, 3
onths [DES] or 1 month [BMS]) and aspirin P81 to 200 mg/day). New antiplatelet agents, clo-
idogrel, or glycoprotein IIb/IIIa blockers, were not
sed because they were not approved in Japan.
Hypertensive patients were defined as those with
lood pressure 140/90 mm Hg or those already
aking antihypertensive drugs. Diabetic patients were
efined as those with fasting blood glucose 126
g/dl or those already taking oral drugs for diabetes
ellitus or receiving insulin therapy. Obesity was
efined as body mass index 26.4 kg/m2. Acute
oronary syndrome (ACS) included acute myocardial
nfarction with/without ST-segment elevation as de-
ned by the Joint European Society of Cardiology/
merican College of Cardiology Committee and
nstable angina was defined according to the Braun-
ald classification. DES were not implanted at the
ulprit lesion(s) of ACS but at additional sites of
evere stenosis. Written informed consent was ac-
uired from all patients. This protocol was approved
y the Osaka Police Hospital Ethical Committee.
ngioscopic procedures and evaluations. Catheter-
zation was performed by a femoral, brachial, or
adial artery approach using a 6- or 7-F
heath and catheters. The coronary angio-
ram was recorded by the Advantx medi-
al system (GE Yokogawa, Tokyo, Japan).
he angioscope RX-3310A and MV-
010A (Machida, Tokyo, Japan) and optic
ber DAG-2218LN (Machida) were
sed. Angioscopic observations were made
hile blood was cleared away from view by
he injection of 3% dextran-40 as previ-
usly reported (5). Stent coverage by neointima,
esion color, and thrombus at the stented lesion
ere evaluated by angioscopy. Lesion color was
lassified into 4 grades (0  white, 1  slight
ellow, 2  yellow, 3  intensive yellow) compared
ith the standard colors as we have previously
eported (3), and the maximum color grade was
etermined for each stented lesion. Stent coverage
as classified into not covered (Grade 0), covered
y thin layer (Grade 1), or buried under neointima
Grade 2), as previously reported (6). Maximum
nd minimum stent coverage was determined for
ach stented lesion. A stent that was buried under
eointima (Grade 2) was identified as such if the
tent strut was not visible under neointima or the
tent strut was visible through the neointima but
as below the level of neointima surface. A stent
hat was covered by a thin layer (Grade 1) was
dentified as such if the stent strut was visible on the
essel surface but was covered by a thin layer.
A B B
A N D
ACS
BMS
DES
PCI
intervresence or absence of all combinations ofR E V I A T I O N S
A C R O N YM S
acute coronary syndrome
bare-metal stent(s)
drug-eluting stent(s)
percutaneous coronarystent
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618overage, lesion color, and thrombus were judged
or each stented lesion. Thrombus was defined as
hite or red material that had cotton-like or ragged
ppearance or that presented fragmentation with or
ithout protrusion into the lumen or was adherent
o the luminal surface. Because we previously re-
orted (3) that a yellow lesion is more thrombo-
enic than a white lesion, we recorded the color of
he lesion and thrombus adhering directly to the
esion. The neointima underlying any thrombus at
he site of strut coverage was graded for the pres-
nce or absence of yellow plaque. Angioscopic
valuations were made by two angioscopic special-
sts blinded to patient characteristics and timing of
xamination (baseline or follow-up), and in case of
isagreement, a third reviewer served as an arbitra-
or. Inter- and intraobserver reproducibilities for
nterpretation of angioscopic images (6) were 95%
nd 95%, respectively, for stent coverage (100% and
00%, respectively, for judging stent coverage of
rade 2 or not), 85% and 95%, respectively, for
laque color, and 90% and 100%, respectively, for
hrombus.
tatistics. Continuous data were presented as mean
SD. Comparisons were made between baseline
nd follow-up by using paired Student t test or
ilcoxon signed rank test. Subgroups were com-
ared by unpaired Student t test or chi-square test.
value of p  0.05 was regarded as statistically
ignificant.
E SULTS
ngioscopic ﬁndings on neointima. Patient and le-
ion characteristics are presented in Tables 1 and 2,
espectively. Neointima coverage (Fig. 1) of DES
as poor. A majority of stents showed Grade 1 or
ess, and BMS had greater neointimal coverage,
hich is consistent with previous reports (6–9).
he maximum yellow color grade of the stented
esion increased significantly (Fig. 2) from baseline
o follow-up. There were subgroups of patients in
hom maximum yellow color grade increased
42%), did not change (42%), or decreased (16%)
rom baseline to follow-up. Even among lesions
ithout yellow plaque at baseline, yellow plaque
as detected in 94% (17 of 18) of lesions at
ollow-up. Yellow plaque was detected at follow-up
n the original vessel wall under the stent where the
tent coverage was Grade 0 or 1, and was also
etected in the newly formed neointima over the
tent where the stent coverage was Grade 2.
rade-2 neointima newly formed over DES had ttherosclerotic yellow plaque in 30% of lesions (33%
f lesions even among those without yellow plaque
t baseline). Yellow plaque was observed both in the
ewly formed neointima and in the original vessel
all after DES implantation. In contrast to DES,
MS had greater coverage predominantly by white
rade-2 neointima.
ngioscopic ﬁndings of thrombus. The prevalence of
Table 1. Patient Characteristics
Characteristic DES BMS
Patients, n 57 12
Age, yrs 68 9 61 12
Male gender, n (%) 49 (86) 9 (75)
Acute coronary syndrome* 14 (25) 1 (8)
Prior MI 19 (33) 3 (25)
Number of diseased vessels
1 vessel 29 (51) 9 (75)
2 vessels 21 (37) 2 (17)
3 vessels 7 (12) 1 (8)
Coronary risk factors
Hypertension 42 (74) 6 (50)
Diabetes mellitus 20 (35) 3 (25)
Current smoking 11 (19) 4 (33)
Obesity 9 (16) 2 (17)
Serum lipid levels at baseline, mg/dl
Total cholesterol 209 37 195 36
LDL cholesterol 121 32 114 29
HDL cholesterol 49 13 51 11
Triglyceride 159 122 134 78
Serum lipid levels at follow-up, mg/dl
Total cholesterol 185 30 193 35
LDL cholesterol 101 30 108 33
HDL cholesterol 53 15 52 10
Triglyceride 140 105 168 117
Medications at baseline
Aspirin† 53 (95) 10 (83)
Ticlopidine† 51 (89) 3 (25)
Statins 21 (37) 6 (50)
ACEI/ARB 23 (40) 2 (17)
Medications at follow-up
Aspirin 53 (95) 12 (100)
Ticlopidine 41 (72) 4 (33)
Statins 38 (67) 8 (67)
ACEI/ARB 28 (49) 3 (27)
Follow-up interval, months 10 3 6 3
Unless indicated otherwise, data are given as n (%) or mean  SD. *Acute
coronary syndrome includes acute MI with/without ST-segment elevation
deﬁned by the Joint European Society of Cardiology/American College of
Cardiology Committee, and unstable angina deﬁned according to the Braun-
wald classiﬁcation. †n (%) of patients who were already taking this drug
before PCI; dual anti-platelet therapy with aspirin and ticlopidine was started
as soon as decision was made to perform PCI.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin recep-
tor blocker; BMS  bare-metal stent(s); DES  drug-eluting stent(s); HDL 
high-density lipoprotein; LDL  low-density lipoprotein; MI  myocardial
infarction; PCI  percutaneous coronary intervention.hrombus was higher on the yellow areas than on
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619he white areas at follow-up (Fig. 4). Thrombus was
etected on yellow and/or Grade-0/1 neointima
Fig. 3). However, when stent strut coverage was
hite Grade-2 neointima, thrombus was never
etected. All thrombi were mural, none was occlu-
ive, and none was detectable by angiography.
mong those who received BMS, thrombus was
etected in only 1 patient in the area where the
tent was not covered by neointima (Grade 0).
Representative angioscopic pictures of DES-
mplanted lesions are presented in Figure 5. Rep-
esentative cases of yellow neointima formed over
ES are presented in Figures 6 and 7.
I SCUS S ION
lthough DES have significantly reduced the rate
f restenosis, late stent thrombosis has emerged as a
erious problem. We previously reported (5,10) that
ngioscopic findings in BMS consist of gradual
overage by white neointima, with a reduced
hrombogenic potential. Yellow plaque formation
n neointima was never observed in BMS within 12
onths of follow-up according to our experience
Table 2. Lesion Characteristics
Characteristic DES BMS
Target vessel
LAD 27 (47) 8 (67)
LCX 6 (11) 1 (8)
RCA 23 (40) 3 (25)
LMC 1 (2) 0 (0)
Lesion type*
A 1 (2) 0 (0)
B1 6 (11) 0 (0)
B2 35 (61) 11 (92)
C 15 (26) 1 (8)
Lesion length, mm
10 3 (5) 0 (0)
10–20 40 (70) 11 (92)
20 14 (25) 1 (8)
Restenotic lesion 5 (9) 0 (0)
CTO lesion 5 (9) 0 (0)
Stent size in diameter, mm 3.1 0.4 3.2 0.5
Total stent length, mm 25 15 16 3
Maximum inﬂation pressure, atm 15 3 13 4
Total inﬂation time, min 2 5 2 2
Diameter stenosis at follow-up, % 10 18 23 13
Unless otherwise indicated, data are given as n (%) or mean  SD. *Lesion
type according to American College of Cardiology/American Heart Associa-
tion classiﬁcation.
CTO  chronic total occlusion; LAD  left anterior descending coronary
artery; LCX left circumﬂex coronary artery; LMC left main coronary artery;
RCA  right coronary artery; other abbreviations as in Table 1.nd previous reports. In the present study, weemonstrated that DES are poorly covered by
eointima at 10 months, a finding consistent with
hose in previous reports (6–9). In addition to poor
eointimal coverage, Grade-2 neointima newly
ormed over DES had atherosclerotic yellow plaque
n 30% of lesions (33% of lesions even among those
ithout yellow plaques at baseline). Yellow plaque
ormation was also enhanced in the vessel wall
nderneath the stent after DES implantation. The
rea with yellow plaque was found to be more
hrombogenic than the area without yellow plaque,
nd Grade-2 neointima without yellow plaque
ailed to show any thrombus.
tent coverage by neointima and thrombogenic poten-
ial of the stented lesion. The healing process of a
tented vessel has been widely investigated and
eported (11–14) both for BMS and DES. The
arliest change is the presence of thrombus followed
y proliferation of smooth muscle cells and endo-
helial cells. In native coronary arteries, the throm-
ogenic potential after exposure of the lipid core is
xtremely high, and it is well known that coverage
f the lipid core by thick fibrous tissue reduces the
hrombogenic potential of the culprit lesion. An-
ioscopic studies of BMS (5,10) revealed that cov-
rage of the stent struts by white smooth neointima
s associated with absence of thrombus formation,
specially after 12 months, suggesting that the
eointima sealed the yellow plaque underneath the
tent, thus stabilizing the lesion.
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DES BMS
100%
Max Min
Grade 2 (Buried under neointima)
Grade 1 (Covered by a thin layer)
Grade 0 (No coverage)
Figure 1. Maximum and Minimum Neointima Coverage of
Stent Struts in DES and BMS at Follow-Up
Majority of neointima coverage was Grade 1 (covered by thin
layer) in drug-eluting stents (DES), but was Grade 2 (buried
under neointima) in bare-metal stents (BMS).
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620Although the DES reduced the restenosis rate
15–24) by preventing smooth muscle cell prolif-
ration, it increased the rate of stent thrombosis
Baseline Follow-up
*p=0.0008 vs. baseline
mean+SD     
*
Changes in Maximum Yellow Color Grade From Baseline to
in DES
yellow color grade increased signiﬁcantly from baseline to follow-up
eluting stent (DES) implantation (1.4  1.1 vs. 1.9  0.6, p  0.0008).
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Figure 3. Incidence of Each Status of Neointima After DES and
Status of neointima was deﬁned by the combination of neointima c
(presence or absence). Incidence of each neointima status among a
Because each stent may have multiple incidences of neointima, sum
ered mainly by Grade-1 neointima; BMS was covered mainly by Gra
was detected in 30% of lesions in DES, but was never detected in B
but was never detected on white Grade-2 neointima.1,25–28) after 1 year (very late stent thrombo-
is), a result rarely seen in BMS. Late stent
hrombosis may be caused by the poorly formed
eointima over DES that has failed to cover and
tabilize underlying thrombogenic yellow plaque.
n the present study, we showed that areas with
ellow plaque are more thrombogenic than those
ithout yellow plaque. Furthermore, we demon-
trated for the first time that yellow plaque
ormation was promoted both in the newly
ormed neointima and in the original vessel wall
nderneath the DES at 10 months after implan-
ation. On the other hand, yellow neointima was
ot observed within 1 year after BMS implanta-
ion. These newly formed yellow plaques ap-
eared to have increased the thrombogenic po-
ential of DES-implanted lesions. We noted a
rend toward regression of yellow plaque with a
eduction of thrombogenic potential (healing)
nd a trend toward progression of yellow plaque
ith the increase of thrombogenic potential;
herefore, where yellow plaques are newly formed
hey may increase the potential for thrombosis in
ES. The formation of yellow neointima was not
ssociated with the use of dual antiplatelet ther-
py at follow-up.
Because both the stent itself and yellow plaque
ave thrombogenic potential, exposure of either
BMS
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621omponent would increase the thrombogenic
otential of the lesion. Indeed, in the present
tudy (Fig. 3), thrombus was detected where stent
as not covered by neointima (Grade 0) or where
ellow plaque was present at the lesion. Grade-1
eointima formed over DES may be inadequate
o reduce the thrombogenic potential of the stent
tself or may have thrombogenic potential itself,
ecause thrombus was detected in areas DES was
overed by white Grade-1 neointima. Although
oth poor stent coverage (Grade 0 or 1) and
ellow color were risk factors for thrombus for-
ation, the odds ratio of thrombus formation was
igher for yellow (vs. white) lesions than for
esions with Grade-0/1 (vs. Grade-2) stent cov-
rage (18.2 [95% confidence interval: 2.3 to
44.1] vs. 5.3 [95% confidence interval: 1.4 to
9.8]), so yellow color appears to be more con-
ributory to thrombus formation than poor stent
overage. It should be noted that thrombus was
ot detected when stent struts were buried under
white neointima (white Grade-2 neointima).
his situation potentially represents the ideal
tate of vascular healing after stent implantation.
owever, these findings need to be validated in a
arge cohort of patients in future studies.
Figure 5. Grading Scheme of Angioscopic Evaluation
(A) A case of a drug-eluting stent (DES) well covered by white smo
partially seen through neointima but was below the level of the ne
(Grade 1). Yellow plaque or thrombus was not detected. Stent was
a thin layer of neointima (Grade 1). Yellow plaque was detected in
detected. Stent was seen above the level of the neointima surface.
tima (Grade 2). No thrombus was observed. (E) A case of a thrombu
neointima (Grade 0).Finn et al. (29) previously reported in histo-
ogic studies that a lack of endothelial strut
overage is the single best correlate of late stent
hrombosis. Since re-endothelialization after
ES implantation is impaired, it is likely that
ipid transport into the neointima is enhanced
nd therefore may result in early atherosclerotic
hanges such as foam cell formation with pro-
ression of atherosclerosis. Newly formed athero-
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Figure 4. Lesion Color and Prevalence of Thrombus on DES-Imp
Lesions
Thrombus was detected signiﬁcantly more often on the yellow area
the white area at follow-up after drug-eluting stent (DES) implantat
neointima (Grade 2) without yellow plaque or thrombus. Stent is
ima surface. (B) A case of DES with a thin layer of neointima
above the level of the neointima surface. (C) A case of DES with
original vessel wall underneath the stent, but thrombus was not
A case of DES with partially invisible coverage by yellow neoin-
n the yellow plaque under the DES, which was not covered by. white
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622clerotic lesions will eventually result in necrotic
ore formation from death of infiltrated macro-
hages through apoptosis followed by thin fi-
rous cap formation, which may rupture and lead
o luminal thrombosis (30).
tudy limitations. In this study, we examined only
irolimus-eluting stents; therefore the results of this
tudy cannot be applied to other DES. The patients
ho underwent angioscopy received heparin, aspi-
in, and ticlopidine, but not clopidogrel or glyco-
rotein IIb/IIIa inhibitors, so the impact of the
atter drugs was not assessed. It is unknown if the
ngioscopically defined thin layer of neointima
onsists of a few layers of smooth muscle cells or a
Figure 6. A Representative Case of Yellow Neointimal Formatio
A 64-year-old man with silent myocardial ischemia received percuta
in the mid right coronary artery (yellow arrows). He had hyperchol
and angioscopic images immediately after stenting (A) and at 12-m
neointima (Grade 2, red arrow) at 12-month follow-up. DES  drug
Figure 7. A Representative Case of Yellow Neointima Formation
A 44-year-old man with stable effort angina received percutaneous
proximal left anterior descending coronary artery (yellow arrows). H
tes mellitus. Angiographic and angioscopic images immediately afte
was covered by yellow neointima (Grade 2, red arrow) at 12-month folayer of endothelial cells and also if the neointima
as mature endothelial function. Using angioscopy,
e can, however, evaluate the antithrombogenic
unction of the layer by the absence or presence of
hrombus on the surface. There are some limita-
ions in the angioscopic observations. Imaging is
imited to the surface of the coronary lumen. It is
lso difficult to evaluate the angioscopic findings
uantitatively, thus the yellow gradation of plaque
nd neointimal stent coverage was evaluated using a
ery discontinuous semiquantitative scoring system.
natomic complexity such as a tortuous and angu-
ated vessel may have limited a complete circumfer-
ntial view of the vessel. Because we performed
ver DES
us coronary intervention (PCI) with a Cypher stent (3.5  23 mm)
rolemia but not hypertension or diabetes mellitus. Angiographic
h follow-up (B) are presented. The stent was covered by yellow
ting stent.
er DES
nary intervention (PCI) with Cypher stent (3.5  18 mm) in the
ad hypercholesterolemia but did not have hypertension or diabe-
enting (A) and at 12-month follow-up (B) are presented. Stentn O
neo
este
ontOv
coro
e h
r stlow-up.
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623ollow-up at only one point in time, further changes
n the appearance of neointima are left to be
larified by the repeated follow-ups. The relation-
hip between angioscopically detected thrombogenic
esion and the risk of stent thrombosis as a clinical
vent needs to be demonstrated in a prospective
ong-term study and with a larger sample size.
ONCLUS IONS
irolimus DES show poor neointimal coverage andsirolimus-eluting stents: angioscopic 1093–9.esions at 10-month follow-up. The yellow areas
ere associated with an increased incidence of
ural thrombus, and complete coverage with white
eointima was not, suggesting a higher risk of stent
hrombosis in newly formed yellow lesions after
irolimus DES implantation.
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